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Mutations affecting NPM1 (nucleophosmin) are the most
common genetic lesions found in acute myeloid leukemia
(AML). NPM1 is one of themost abundant proteins found in the
nucleolus and has links to the MDM2/p53 tumor suppressor
pathway. A distinctive feature of NPM1mutants inAML is their
aberrant localization to the cytoplasm of leukemic cells. This
mutant phenotype is the result of the substitution of several
C-terminal residues, including one or two conserved trypto-
phan residues, with a leucine-rich nuclear export signal. The
exact molecular mechanism underlying the loss of nucleolar
retention, and the role of the tryptophans, remains unknown. In
this studywehave determined the structure of an independently
folded globular domain in the C terminus of NPM1 using NMR
spectroscopy, and we report that the conserved tryptophans are
critical for structure. This domain is necessary for the nucleolar
targeting of NPM1 and is disrupted by mutations in AML with
cytoplasmic NPM1. Furthermore, we identify conserved sur-
face-exposed lysine residues that are functionally rather than
structurally important for nucleolar localization. This study
provides new focus for efforts to understand the pathogenesis of
AMLwith cytoplasmic NPM1 andmay be used to aid the design
of small molecules that target the C-terminal domain of NPM1
to act asnovel anti-proliferative andanti-leukemia therapeutics.
The gene encoding nucleophosmin (NPM1) is mutated in
50–60% of normal karotype adult acute myeloid leukemia
(AML),2 making NPM1 mutations the most common genetic
lesions identified to date in de novo AML. NPM1 (nucleophos-
min, also known as B23 or numatrin) is a ubiquitously
expressed protein that belongs to the nucleoplasmin family of
nuclear chaperones. Found predominantly in the nucleolus,
NPM1 is used as a marker for the granular component (1–3)
(the site of pre-ribosomal subunit assembly (4)). NPM1 rapidly
shuttles between the nucleoplasm and the cytoplasm (5–7)
serving as a chaperone for both nucleic acids and proteins
(8–11). NPM1 is essential for embryonic development (12) and
appears to modulate diverse molecular functions, including
ribosome biogenesis (13–16) and genomic stability (12). NPM1
is overexpressed in a number of solid tumors (17), is linked to
the p53/MDM2 pathway via the tumor suppressor ARF (18–
22), and is a transcriptional target of Myc (23, 24).
A distinctive feature of NPM1mutants in AML is their aber-
rant localization to the cytoplasm of leukemic cells (NPMc
AML) (25). Two consequences of mutation-related sequence
changes at theC terminus ofNPM1promote aberrant cytoplas-
mic localization of mutant NPM1 proteins in NPMc AML.
First, generation of an additional leucine-rich nuclear export
motif reinforces Crm1 (XpoI)-dependent nuclear export of
NPM1 leukemic mutants (26). Second, there is loss of trypto-
phan residues Trp288 and Trp290 (or Trp290 alone) that deter-
mine NPM1 nucleolar localization (25, 27, 28). However, the
precise molecular mechanisms that regulate the steady state
distribution of NPM1 are unknown. In this study, we tested the
hypothesis that NPM1 tryptophans Trp288 and Trp290 are crit-
ical structural components of an independently folded domain
that is essential for nucleolar targeting of NPM1. These studies
provide a structural basis for understanding the mechanisms
underlying NPMc AML.
EXPERIMENTAL PROCEDURES
Reagents—Mutants NPM1 W288A/W290A and NPM1
F268A/F276A were made by site-directed mutagenesis and
mutants A and E by PCR using appropriate primers. NPM1
C-terminal domain variants, with the exception of mutant A,
were cloned into a modified pRSETA vector (Invitrogen)
expressing the protein fused to a tobacco etch virus protease-
cleavable His6-tagged lipoyl domain from Bacillus stearother-
mophilus. Proteins were expressed in Escherichia coli strain
C41 and purified using Ni2-chelating affinity chromatogra-
phy. Fusion proteins were cleaved by tobacco etch virus prote-
ase digestion and removed in a second affinity step before
concentration and final purification by size exclusion chroma-
tography on a GF30 column (Amersham Biosciences). For iso-
topic labeling, K-MOPS minimal media containing 15NH4Cl
and/or [13C]glucose was used. Mutant A C-terminal domain
was made using a Liberty CEMmicrowave peptide synthesizer
(Matthews, NC) and standard Fmoc (N-(9-fluorenyl)methoxy-
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carbonyl)/t-butyl chemistry and purified by reverse-phase high
pressure liquid chromatography. All C-terminal constructs have
an additional two glycine residues at the N terminus as a result of
the cloning andpurification strategy; residue numbering is in con-
text of the full-length protein and omits these glycines.
SDS-PAGEand electrospraymass spectrometrywere used to
confirm proteins were of the expected mass and to assess their
purity. Protein concentration was determined spectroscopi-
cally using a Varian Cary 500 spectrometer (Varian, NC), and
extinction coefficients were calculated for 280 nm (29, 30). All
reagents were purchased from Sigma and were Anal-R grade or
higher, except for isotopically enriched reagents, which were
purchased from Cambridge Isotopes (Cambridge, UK).
Spectroscopic Measurements—The NMR spectra were
recorded on Bruker Advance-800, Advance-II 700, and
Advance-600 spectrometers. Two-dimensional NOESY,
TOCSY, DQF-COSY, 15N-HSQC, constant time 13C-HSQC
and 13C-TOCSY were recorded at 298 K. The mixing times
chosen were 80 ms for TOCSY and
120 ms for NOESY. Spectra were
referencedrelative toexternal sodium
2,2-dimethyl-2-silapentane-5-sulfon-
ate for signals of proton and carbon,
or liquidammoniumfor thatof nitro-
gen. Approximately half the Hb res-
onances were assigned stereospecif-
ically using a combination of HNHB
and DQF-COSY spectra. All the
Val(H) and Leu(H) resonances
were assigned stereospecifically
using a 10% 13C-labeled sample of
NPM1 C-terminal domain (31). All
the NMR spectra were analyzed
with Sparky (32).
All samples used for structure
determinationwere 1.2mMandpre-
pared in 10 mM MES, pH 6.5, 150
mM NaCl, 5 mM dithiothreitol,
0.02% sodium azide, and 5% D2O
(homonuclear samples were in a
deuterated version of this buffer).
For hydrogen exchange experi-
ments, the 15N-labeled NPM1
C-terminal domain was exchanged
into NMR buffer containing 100%
D2O using a NAP-10 column
(Amersham Biosciences), and a
series of 1H-15N-FHSQC spectra
(33) were recorded over the course
of 6 h.All one-dimensional 1HNMR
experiments were conducted in bio-
physics buffer (10 mM KPi, pH 6.5,
150 mM NaCl, 5% D2O).
Structure Determination—The
distance constraints derived from
the NOESY spectra were classified
into four categories corresponding
to inter-proton distance constraints
of 1.8–2.8, 1.8–3.5, 1.8–4.75, and 1.8–6.0 Å, respectively.
Hydrogen bond constraints of 1.8–2.1 Å were imposed on the
distance between the hydrogen and the acceptor oxygen,
whereas another constraint of 2.7–3.1 Å was imposed on the
distance between the donor nitrogen and the acceptor oxy-
gen. Torsion angle constraints were obtained from stereo-
specific assignment of residue side chains and incorporated
in the structure calculation, along with the backbone and 
angle constraints determined with the program TALOS (34).
The structures were calculated using a standard torsion
angle dynamics simulated annealing protocol with the pro-
gram CNS (35). 150 structures were accepted out of 150,
produced with no distance violations greater than 0.25 Å,
and no angle violations greater than 5°. Of these the 20 low-
est energy structures were selected for presentation and sta-
tistical representation.
Circular Dichroism—CD spectra of NPM1 were recorded
between 260 and 190 nm at 30–60 M in the biophysics buffer
FIGURE 1. Solution structure of the C-terminal domain of nucleophosmin. A, overlay of the backbone
atoms of the 20 lowest energy structures in stereo. B, schematic representation of the lowest energy structure
coloredblue to red from theN toC terminus (sameorientation as inA). Preparedusing theprogramPyMOL (53).
Structure of C-terminal Domain of NPM1
AUGUST 22, 2008•VOLUME 283•NUMBER 34 JOURNAL OF BIOLOGICAL CHEMISTRY 23327
using a Jasco-J815 spectropolarimeter (Jasco Inc., Easton, MD)
and a 1-mmpath length cuvette. The base line due to the buffer
only was recorded and subtracted prior to normalizing the data
for concentration. Thermal denaturation was followed at 222
nmwith heating from 277 to 371 K at a rate of 1 Kmin1. Data
were fit to a standard two-state denaturation as described else-
where (36).
Immunofluorescence—Full-length NPM1 variants were
cloned into the mammalian expression vector pEGFP-C1
(BD Biosciences). NPM1 variants were thus expressed in
vivo with an N-terminal enhanced green fluorescent protein
(eGFP) tag.
NIH-3T3murine fibroblasts were grown inDulbecco’smod-
ified Eagle’s mediumGlutaMAXTM (Invitrogen) supplemented
with 10% fetal calf serum. A day before transfection a confluent
flask of cells was subcultured at a 1:8 dilution in 6-well plates
containing glass coverslips. Transfection was performed using
Lipofectamine 2000 (Invitrogen) as per the manufacturer’s
instructions. After 24 h coverslips were removed, washed with
PBS, and fixed in 4% paraformaldehyde for 20 min. Cells were
permeabilized with PBS 0.1% Triton X-100 prior to blocking
for 30 min with 20% fetal calf serum, 0.5% Tween 20 in PBS
(FATS). Cells were stained with mouse anti-fibrillarin (ab4566,
AbCam, UK) at 1:500 in FATS for 1 h. After three washes with
PBS 0.1% Triton X-100, the cells were incubated in the dark
for 1 h with Alexa FluorTM 594-conjugated goat anti-mouse
antibody (Molecular Probes, Leiden, Netherlands) at 1:200 in
FATS. The coverslips were dried in air andmounted using Flu-
oromount-GTM (Southern Biotech, Birmingham, AL). Images
were collected using an MRC-2000 plus confocal apparatus
(Bio-Rad) mounted on a Nikon eclipse E800 microscope using
the60 oil objective lens.
RESULTS
The Structure of the NPM1 C-terminal Domain—Manual
inspection of the sequence of NPM1, with assistance from the
secondary structure prediction tool Jpred (37), indicated the
potential for three short helices separated by short loops within
the last 50 residues. This potential domain is separated from the
N-terminal oligomerization domain by an 120-residue acid-
rich region that is predicted to be disordered. The DNA
sequence corresponding to residues 243–294 of NPM1 was
cloned and overexpressed in E. coli. Inspection by SDS-PAGE
and electrospray-mass spectrometry following purification
identified a pure protein of the expected mass. Both one-di-
mensional 1H NMR and 15N-HSQC experiments produced
well dispersed spectra that are characteristic of a folded protein
(Fig. 3A).
The NMR spectra of residues Ser243 to Leu294 of NPM1were
assigned, and the solution structure was determined using
standard techniques (38, 39). Residues 244–294 adopt a well
defined tertiary structure with a root mean square deviation of
0.4Å for backbone atoms (Fig. 1A). Experimental restraints and
structural statistics for the 20 accepted lowest energy structures
are summarized in Table 1. The coordinates for the structure
are available from the Protein Data Bank (entry code 2vxd).
The C-terminal domain of NPM1 forms a well defined right-
handed 3-helix bundle (Fig. 1B). Helix 1 is formed of residues
Val244 to Glu256, with Lys257 and Gly258 then forming an
H-bonded turn into the first loop Gly259–Pro264. Helix 2 runs
from Glu265 to Phe276 until the second loop of Arg277–Asp280,
and helix 3 is composed of residuesGln281 to Lys292. The core of
the protein is formed largely by aromatic residues (Tyr271,
Phe268, Phe276, Trp288, and Trp290) with further contribution
from residues Met251, Ile255, Leu261, Val272, and Leu287.
Sequence alignment of homologous proteins (Fig. 2D)
reveals the hydrophobic core is largely conserved, with
Trp288, Trp290, and Phe268 and Phe276 strictly conserved.
Deletions, seen in the more distantly related proteins from
Lytechinus pictus and Asterina pectinifera, are confined
solely to loop 1, and it is highly likely that the fold is con-
served throughout these species. Other residues strictly con-
served are Pro262, which ends loop 1, and three lysines as
follows: Lys263 and Lys267 cluster on the surface of the pro-
tein, whereas Lys248 appears to form a salt bridge with Asp286
(Fig. 2C) and may be structurally important.
The NPM1 C-terminal domain has no significant sequence
similarity to any protein or domain, but a search for structurally
similar proteins using the program DALI (40) returned several
matches, among which the most significant single domain pro-
teinwas the recently published archaeal ribosomal protein S17e
(41).
Effect of the Leukemia Mutations on the Structure of the
NPM1 C-terminal Domain—NPMc mutations alter the
sequence of theC terminus of the third helix in the structure. In
themost commonmutation, mutant A, the wild-type sequence
WQWRKSL is replaced by the sequence CLAVEEVSLRK,
whereas in the less commonmutant E it is replaced withWQS-
TABLE 1
Summary of conformational constraints and statistics for the 20





Medium range (2 i j  4) 219
Long range (i j 4) 118
1 angle constraints 15
ALOS constraints 77
Hydrogen bond constraints 50
Total 1498
Statistics for accepted structures
Statistics parameter (S.D.)
r.m.s.d.a for distance constraints 0.0084 0.0003 Å
r.m.s.d. for dihedral constraints 0.345 0.029o
Mean CNS energy term (kcalmol1 S.D.)
E (overall) 50.3 4.2
E (van der Waals) 15.8 2.9
E (NOE and hydrogen bond constraints) 3.1 .2
E (-1 dihedral and TALOS constraints) 0.56 0.1
r.m.s.d. from the ideal geometry (S.D.)
Bond lengths 0.0015 0.00009 Å
Bond angles 0.32 0.007o
Improper angles 0.24 0.013o
Average atomic r.m.s.d. from the mean structure (S.D.)
Residues 3–54 (N, C-, C atoms) 0.40 0.07 Å
Residues 3–54 (all heavy atoms) 0.94 0.08 Å
Structural quality
Residues in most favored region of
Ramachandran plot
94.1%
Residues in additional allowed region of
Ramachandran plot
5.2%
Residues in disallowed region of
Ramachandran plot
0.3%
a r.m.s.d.means rootmean square deviation;NOEmeans nuclearOverhauser effect.
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LAQVSLRK (Fig. 3C). Several of the
altered residues are at the interface
between helix 3 and helices 2 and 1
and contribute to the hydrophobic
core of the domain. In the NPMc
mutants, these residues are replaced
by smaller amino acids, and this
would be predicted to greatly desta-
bilize the domain. To test this
hypothesis, we used NMR spectros-
copy. The one-dimensional 1H
NMRspectra of bothmutantsA and
E show a decrease in dispersion
compared with NPM1wt (Fig. 3A),
indicative of a loss of tertiary struc-
ture. Fig. 3B shows the CD spectra
of NPM1wt and mutants A and E
as a function of temperature.
NPM1wt describes a sigmoidal
unfolding transition typical of a
folded protein, whereas mutant A
shows no evidence of any such
transition and yields a trace simi-
lar to that expected from an
unstructured protein. Mutant E
shows an intermediate response;
there is evidence of a transition,
FIGURE2.Sequencealignmentand thepositionsof structurallyand functionally important residues.A–C, schematic representationsof theC-terminal domain
of nucleophosmin colored blue to red from theN toC terminuswith structurally and functionally important residues highlighted as sticks. Figurewas prepared using
theprogramPyMOL (53).A, Trp288 andTrp290 showing their positions in the core.B,Phe268 andPhe276, for comparisonwithA.C, residues Lys248 andAsp286 that form
a salt bridge and Lys263 and Lys267, which cluster on the surface. D, structure-based sequence alignment of the C-terminal domain of nucleophosmin and related
proteins. SequenceswerealignedusingtheprogramsClustalW(54)andJalview(55)andshadedblueaccordingto thedegreeofconservation.ProteinsandtheirNCBI
accession numbers are as follows: nucleophosmin 1 fromHomo sapiens gi:10835063,Musmusculus gi:56206422,Danio rerio gi:31418910,Gallus gallus gi:45383996.
NO38 from Xenopus laevisgi:64919,Mitotic Apparatus Protein p62 from L. pictusgi:1841528 and nucleolar protein fromA. pectiniferagi:18146874.
1 M-1.cm-1-
FIGURE 3.Biophysical analysis of nucleophosmin variants.A, amide region of one-dimensional 1HNMR spectra
oftheC-terminaldomainsofthenucleophosminvariants:wild-type(wt);mutantA(MutA);mutantE(MutE);W288A/
W290A(DW), andF268A/F276A.Allmutantsshowadecrease indispersioncomparedwithwild type, indicatingthat
all mutants are unfolded. B, traces from thermal melts of nucleophosmin C-terminal domain variants followed by
differential absorbance at 222 nmby circular dichroism spectroscopy. The blue points correspond towild type (wt),
the green to Mutant E (Mut E), and the red to Mutant A (Mut A). Wild-type describes a typical two-state sigmoidal
transition. Differential scanning calorimetry was used to corroborate this result and agreed within experimental
error to a Tm of 62 °C andHunfolding of 40 kcalmol
1. Mutant A shows no sign of any transition, whereasmutant E
exhibits some degree of transition although appears to never fully occupy the folded state of wild-type NPM1. C,
table displaying the C-terminal sequences of wild-type NPM1 comparedwithmutants A and E. All naturally occur-
ring mutations found in AML, including A and E, are because of a frameshift that results in the substitution of the
extremeCterminus(includingoneorbothofthetryptophansTrp288andTrp290)witha leucine-richNES.Substituted
residues are colored red and those forming theNESmotif are underlined.
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but the protein never appears to fully occupy the folded state
of the wild type.
These results suggest that the mutations found in AML lead
to the destabilization of the C-terminal globular domain of
NPM1. Mutant A, which lacks both Trp288 and Trp290, has no
residual regular secondary structure. Interestingly,mutant E (in
which Trp288 is retained), although largely destabilized, is
clearly not completely unstructured. This mutant may retain
some ability to localize NPM1 to the nucleolus, and this could
explain why it has a stronger nuclear export signal thanmutant
A (42), which itself is completely unfolded.
A Folded C-terminal Domain Is Required for Nucleolar
Targeting—ExpressingNPM1 as an eGFP fusion inmammalian
cells allows for the direct observation of its subcellular localiza-
tion (43). In this manner the mutation of Trp288 and Trp290 to
alanine in NPM1 has been shown to lead to loss of nucleolar
localization and the accumulation of the protein in the nucleus
(27, 28). To date it has not been clear how these residues con-
tributed to the direction of NPM1 to the nucleolus. We have
shown that Trp288 and Trp290 are part of the hydrophobic core
of a folded domain (Fig. 2A), and it would be expected that their
mutation would lead to a loss of structure. Indeed, the NPM1
C-terminal domain with Trp288 and Trp290 mutated to alanine
lacks any distinct tertiary structure (as judged by one-dimen-
sional 1HNMR; see Fig. 3A) and does not undergo a cooperative
unfolding transition when heated (Fig. 3B). This would suggest
that mutation of these residues prevents nucleolar localization
simply by preventing the correct folding of the C-terminal
domain of NPM1. To test this hypothesis, we decided to make
other mutations in the C-terminal domain that would be
expected to disrupt its structure while retaining the trypto-
phans. To this end we chose to mutate phenylalanines 268 and
276 to alanine (F268A and F276A) as these residues are also
strictly conserved, large hydrophobic residues that pack at
the interfaces of the helices andmakemany contacts within the
core (Fig. 2B, and compared with Fig. 2A). As expected the
NPM1 domain containing the F268A/F276A mutations lacks
any distinct tertiary structure (Fig. 3A). We next examined the
effects of these mutations on subcellular localization by trans-
fecting full-length green fluorescent protein-tagged NPM1
F268A/F276A into NIH-3T3 cells. The mutant eGFP-NPM1
F268A/F276A is nuclear and excluded from the nucleolus (Fig.
4), thus proving that nucleolar localization is a property of the
C-terminal domain as a whole.
It has been reported by Falini et al. (27) that re-inserting
Trp288 and Trp290 into mutant A leads to complete relocaliza-
tion to the nucleolus. We investigated the C terminus of this
mutant A C288W/A290W construct and found it to be folded,
as judged by CD and NMR. Presumably, refolding the C termi-
nus of mutant A allows it carry on its normal function within
the nucleolus while making the nuclear export signal unavail-
able to the export machinery. Hence, to better distinguish the
role of the NES from nucleolar targeting, we added the nuclear
export signal from mutant A (LAVEEVSLRK) to the end of
wild-type C-terminal domain with a GGS linker and found the
full-length construct to be nucleolar. This indicates that a loss
of structure and the addition of a nuclear export signal are nec-
essary to cause the aberrant cytoplasmic localization observed
in NPMc AML.
Functionally Important Residues in the C-terminal Domain
of NPM1—Within the C-terminal domain of NPM1 lysine res-
idues 248, 263, and 267 are strictly conserved and surface-ex-
posed (Fig. 5), thus indicating their potential as functionally
important residues. To examine this, these residues were
mutated to alanine, and the effects on domain stability and
nucleolar localization were monitored.
Although Lys248 is surface-exposed, it appears to form a long
range salt bridge with Asp286. Indeed the mutation K248A sig-
nificantly destabilizes the domain and as such leads to Lys248
being classified as structurally important as opposed to being
directly functional (data not shown).
Lysines 263 and 267 cluster and orientate freely on the sur-
face of the domain (Fig. 5, and as judged by a lack of side chain
nuclear Overhauser effects), and mutation of either Lys263 or
Lys267, or both, increases the stability of the domain in line with
the previously described effects of removing unpaired surface
charges (44). Once established as not structurally detrimental,
the nucleolar localization of the full-length NPM1 mutants
K263A, K267A, and the double mutant K263A/K267A was
studied in vivo. Mutant K263A was partially delocalized to the
FIGURE 4. Cellular localization of C-terminal domain variants, structural
mutants. NIH-3T3 cells were transfected with eGFP tagged full-length
nucleophosmin variants, as indicated. A, wild type (wt); B, mutant A (Mut A);
C, W288A/W290A; D, F268A/F276A (left panel). Cells were co-stained with
anti-fibrillarin antibody to highlight the nucleolus (middle panel). As
expected, wild-type NPM1 is entirely nucleolar andmutant A is entirely cyto-
plasmic. Mutant eGPF-NPM1 W288A/W290A is nuclear and exclusive of the
nucleolus, as too is mutant eGFP-NPM1 F268A/F276A.
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nucleoplasm, and K267A and the double mutant were com-
pletely delocalized (Fig. 6).
As a control, the freely orienting surface lysine Lys250 was
also mutated. The C-terminal mutant K250A was, predictably,
more stable than the wild-type domain yet had no significant
effect on nucleolar localization (Fig. 6). This important result
emphasizes the specific functional requirement of residues
Lys263 and Lys267 for nucleolar localization over any nonspe-
cific charge effects.
DISCUSSION
Nucleophosmin is a member of the nucleoplasmin family of
molecular chaperones and shares the N-terminal pentameriza-
tion domain and central acidic region characteristic of these
proteins. In this study we have shown that NPM1 has an addi-
tional folded domain at its C terminus, which is unique to this
subfamily. Although nucleoplasmin is found throughout the
nucleus, NPM1 is one of the most abundant proteins in the
nucleolus, and this C-terminal domain is necessary for its
nucleolar localization. How it directs the protein to the nucle-
olus is not clear. It seems likely that it binds to a protein or
nucleic acid ligand that is abundant in the nucleolus, and it is
possible that the structural similarity to ribosomal protein S17e
is functionally significant.
The natural product avrainvillamide has been shown to bind to
the C-terminal domain of NPM1 via Cys275 (45) and sensitizes
cells to apoptosis. It seems likely that avrainvillamide competes
with the natural binding partner of this domain. Interestingly,
Cys275 is on the same face as the two lysine residues that we have
shown to be important for nucleolar localization (Fig. 5) suggest-
ing that this region of the domain is involved in ligand binding.
Ribosome biogenesis is metabolically expensive and a rate-
limiting step in cell division and growth. Consequently, riboso-
mal integrity is closely monitored by a variety of pathways (46).
Free ribosomal proteins, for example, activate the tumor sup-
pressor p53 by inhibiting its negative regulatorMDM2.There is
growing evidence that defects in these pathways can lead to
disease. Several blood disorders, for example, are caused by
mutations in ribosomal proteins or in ribosome assembly fac-
tors (47–51), and mutations that prevent ribosomal protein
binding to MDM2 have been reported in human cancers (52).
These pathways also seem to be disrupted in NPMc AML.
NPM1 binds to the p19/ARF tumor suppressor and is also reg-
ulated by other pathways that control cell growth (18–24). It
seems likely that misdirection of p19ARF, or another key regu-
latory molecule that binds NPM1, to the cytoplasm may play a
key role in AML. The results of this study show that the aber-
rant cytoplasmic accumulation of NPM1 in NPMc AML
results from both the gain of a nuclear export signal and the
disruption of the structure of its C-terminal domain.Molecules
FIGURE 5.Electrostatic representationof theC-terminal domain showing
functionally important residues. The electrostatic surface potential of the
C-terminal domain of NPM1 as calculated by the program APBS (56) and col-
ored using a linear color ramp from 20.0 kiloteslas (red) to 20.0 (blue).
Lys263 and Lys267 are required for nucleolar localization, but Lys250 is not (see
Fig. 6). The natural product avrainvillamide bound to Cys275 and displaced
NPM1 from the nucleolus to the nucleoplasm (45).
FIGURE 6. Cellular localization of C-terminal domainmutants, functional
mutants. NIH-3T3 cells were transfected with eGFP tagged full-length
nucleophosmin variants, as indicated. A, wild type (wt); B, K250A; C, K263A;
D, K267A; E, K263A/K267A (left panel). Cells were co-stained with -fibrillarin
antibody tohighlight thenucleolus (middle panel).Wild-typeNPM1 is entirely
localized to the nucleolus, and mutant eGPF-NPM1 K250A is broadly similar.
Mutant eGPF-NPM1 K263A is largely displaced into the nucleoplasm but dis-
plays some residual nucleolar retention. Mutant eGPF-NPM1 267A and the
double mutant eGPF-NPM1 K263A/K267A show no residual nucleolar bind-
ing and are evenly distributed throughout the nucleoplasm.
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that target the C-terminal domain of NPM1 interfere with this
mislocalization could therefore have potential applications in
leukemia therapy.
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